Control BionicsASX:CBL -3.53% OCF Yield % is -12.22 as of Jun. 27, 2026. The stock has 6 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Control Bionics ranks worse than 78.64% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Control Bionics's OCF Yield % or its related term are showing as below:
ASX:CBL'
s OCF Yield % Range Over the Past 10 Years
Min: -114.55 Med: -46.69 Max: -8.72
Current: -12.22
During the past 6 years, the highest OCF Yield % of Control Bionics was -8.72%. The lowest was -114.55%. And the median was -46.69%.
ASX:CBL's OCF Yield % is ranked worse than 78.64% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs ASX:CBL: -12.22
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Control Bionics OCF Yield % Related Terms
Control Bionics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Control Bionics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Control Bionics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a OCF Yield % of -12.22 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #670 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 78.6%.
Is Control Bionics' OCF Yield % too high?
Control Bionics' current OCF Yield % is -12.22. Based on the distribution chart, Control Bionics ranks #670 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #670 out of 852 companies for OCF Yield %. This places Control Bionics in the lower half of its industry. The industry median OCF Yield % is 1.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.79, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current OCF Yield % is -12.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 173.3% above its estimated fair value. The current OCF Yield % is -12.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current OCF Yield % is -12.22 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 